SEC Comment Letter 0000000000-23-012259 to Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc.
Date: Nov. 8, 2023 · CIK: 0001860657 · Accession: 0000000000-23-012259
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275282
Letter
United States securities and exchange commission logo November 8, 2023 James Cullem Chief Executive Officer Allarity Therapeutics, Inc. 24 School Street, 2nd Floor Boston, MA 02108 Re:Allarity Therapeutics, Inc. Registration Statement on Form S-3 Filed November 2, 2023 File No. 333-275282 Dear James Cullem: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Scott E. Bartel, Esq
Show Raw Text
United States securities and exchange commission logo
November 8, 2023
James Cullem
Chief Executive Officer
Allarity Therapeutics, Inc.
24 School Street, 2nd Floor
Boston, MA 02108
Re:Allarity Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 2, 2023
File No. 333-275282
Dear James Cullem:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Scott E. Bartel, Esq